Why the length of recurrence-free survival or 'lead-times' can be misleading. Comment on: Callesen LB, Takacova T, Hamfjord J, Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis.
作者信息
Sorscher Steven
机构信息
Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
出版信息
Ther Adv Med Oncol. 2023 Mar 17;15:17588359231156383. doi: 10.1177/17588359231156383. eCollection 2023.
Abstract
摘要
相似文献
1
Why the length of recurrence-free survival or 'lead-times' can be misleading. Comment on: Callesen LB, Takacova T, Hamfjord J, Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis.为何无复发生存期的时长或“领先时间”可能具有误导性。评论：Callesen LB、Takacova T、Hamfjord J，《接受局部区域治疗的结直肠癌转移患者的循环DNA：系统评价与荟萃分析》
Ther Adv Med Oncol. 2023 Mar 17;15:17588359231156383. doi: 10.1177/17588359231156383. eCollection 2023.
2
Time for a lead-time definition? Author response to 'Why the length of recurrence free survival or "lead-times" can be misleading. Comment on: Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis'.是时候定义提前期了？作者对《为何无复发生存期或“提前期”的时长可能具有误导性。对Callesen LB、Takacova T、Hamfjord J等人的评论：接受局部区域治疗的结直肠癌转移患者的循环DNA：一项系统评价和荟萃分析》的回应
Ther Adv Med Oncol. 2023 Mar 17;15:17588359231156393. doi: 10.1177/17588359231156393. eCollection 2023.
3
Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis.接受结直肠癌转移灶局部区域治疗患者的循环DNA：一项系统评价和荟萃分析。
Ther Adv Med Oncol. 2022 Nov 2;14:17588359221133171. doi: 10.1177/17588359221133171. eCollection 2022.
4
Low rates of loco-regional recurrence following extended lymph node dissection for gastric cancer.胃癌扩大淋巴结清扫术后局部区域复发率较低。
Eur J Surg Oncol. 2009 Jun;35(6):588-92. doi: 10.1016/j.ejso.2008.12.012. Epub 2009 Jan 22.
5
Extracapsular axillary node extension in patients receiving adjuvant systemic therapy: an indication for radiotherapy?接受辅助全身治疗患者的腋窝淋巴结包膜外扩展：放疗指征？
Int J Radiat Oncol Biol Phys. 1997 Jun 1;38(3):551-9. doi: 10.1016/s0360-3016(97)89483-7.
6
Systemic therapy for treating locoregional recurrence in women with breast cancer.治疗乳腺癌女性局部区域复发的全身治疗
Cochrane Database Syst Rev. 2001;2001(4):CD002195. doi: 10.1002/14651858.CD002195.
7
Response to letter to the editor from Dr Rahman Shiri: The challenging topic of suicide across occupational groups.回复拉赫曼·希里博士的来信：职业群体中的自杀这一具有挑战性的话题。
Scand J Work Environ Health. 2018 Jan 1;44(1):108-110. doi: 10.5271/sjweh.3698. Epub 2017 Dec 8.
8
The effect of loco-regional control on distant metastatic dissemination in carcinoma of the nasopharynx: an analysis of 1301 patients.局部区域控制对鼻咽癌远处转移扩散的影响：1301例患者的分析
Int J Radiat Oncol Biol Phys. 1994 Dec 1;30(5):1029-36. doi: 10.1016/0360-3016(94)90306-9.
9
Editorial comment on 'Impact on functional outcome of an adaptive Stroke Unit based system of care for patients undergoing endovascular treatment during pandemic times' by Equiza J et al. published European Stroke Journal.对Equiza J等人发表于《欧洲卒中杂志》的“大流行期间基于适应性卒中单元的血管内治疗患者护理系统对功能结局的影响”的编辑评论
Eur Stroke J. 2022 Sep;7(3):257-258. doi: 10.1177/23969873221100661. Epub 2022 May 27.
10
[Treatment of bilateral neck metastases in laryngeal cancer].[喉癌双侧颈部转移灶的治疗]
Nihon Jibiinkoka Gakkai Kaiho. 1996 May;99(5):661-8. doi: 10.3950/jibiinkoka.99.661.
本文引用的文献
1
Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis.接受结直肠癌转移灶局部区域治疗患者的循环DNA：一项系统评价和荟萃分析。
Ther Adv Med Oncol. 2022 Nov 2;14:17588359221133171. doi: 10.1177/17588359221133171. eCollection 2022.
2
Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences.循环肿瘤 DNA 在 III 期结直肠癌中的应用：超越微小残留病灶检测，评估辅助治疗疗效和复发的临床行为。
Clin Cancer Res. 2022 Feb 1;28(3):507-517. doi: 10.1158/1078-0432.CCR-21-2404. Epub 2021 Oct 8.
3
Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer.术后循环肿瘤 DNA 作为 II 期至 III 期结直肠癌复发风险的标志物。
J Hematol Oncol. 2021 May 17;14(1):80. doi: 10.1186/s13045-021-01089-z.
4
Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy.采用多标志物 DNA 甲基化液体活检技术高效检测和术后监测结肠癌。
Proc Natl Acad Sci U S A. 2021 Feb 2;118(5). doi: 10.1073/pnas.2017421118.
5
Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.循环肿瘤 DNA 作为可切除和不可切除 IV 期结直肠癌的生物标志物：系统评价和荟萃分析。
Eur J Cancer. 2021 Feb;144:368-381. doi: 10.1016/j.ejca.2020.11.025. Epub 2021 Jan 7.
6
Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.局部结肠癌中循环肿瘤 DNA 微量残留病灶的靶向二代测序。
Ann Oncol. 2019 Nov 1;30(11):1804-1812. doi: 10.1093/annonc/mdz390.
7
Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery.用于监测结直肠癌手术后患者肿瘤存在的个体化多重循环肿瘤 DNA 检测。
Sci Rep. 2017 Jan 19;7:40737. doi: 10.1038/srep40737.
8
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.循环肿瘤DNA分析可检测II期结肠癌患者的微小残留病并预测复发。
Sci Transl Med. 2016 Jul 6;8(346):346ra92. doi: 10.1126/scitranslmed.aaf6219.
9
Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery.结直肠癌手术后利用循环肿瘤 DNA 监测疾病负担的分析。
Gut. 2016 Apr;65(4):625-34. doi: 10.1136/gutjnl-2014-308859. Epub 2015 Feb 4.
Zotero 插件